B. E. Weissman

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide

This paper identifies super-enhancer activity in SCCOHT driven by SMARCA4 loss and shows triptolide effectively inhibits tumor growth by targeting TFIIH at super-enhancers.

A Cytoskeletal Function for PBRM1 Reading Methylated Microtubules

This study identifies PBRM1 as the first cytoskeletal reader for SETD2-mediated -tubulin methylation, revealing a new role for PBRM1 in mitotic spindle organization and genomic stability.

Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type

This paper identifies ASS1 deficiency in rare ovarian cancers and shows that ADI-PEG20 inhibits tumor growth in ASS1-deficient models.

Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factor

The paper identifies BRSK2 as a negative regulator of NRF2 by inhibiting protein synthesis through mTOR downregulation, suggesting it as a potential therapeutic target for NRF2-related diseases.

Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type

This study identifies distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient SCCOHT cell lines, revealing altered functional consequences and potential synthetic lethal targets.

Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition

This paper identifies ponatinib as a potent treatment for SCCOHT by inhibiting multiple kinases in preclinical models.